Further studies revealed that the potent HDACi LAQ824 could effectively kill DLBCL cells, and when used in combination with a c-Fos inhibitor, it significantly enhanced anti-tumor activity, offering a new direction for HDACi combination therapy (52). This evidence concerns the gene FOS and diffuse large B-cell lymphoma.